Morning symptoms in rheumatoid arthritis: A defining characteristic and marker of active disease

Scandinavian Journal of Rheumatology

Volumn 40, Issue SUPPL. 125, 2011, Pages 1-5

  Sierakowski, S ^a   Cutolo, Maurizio ^b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROCORTISONE; INTERLEUKIN 6; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; AUTACOID;

ARTHRALGIA; ARTICLE; CIRCADIAN RHYTHM; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE MARKER; ERYTHROCYTE SEDIMENTATION RATE; FUNCTIONAL DISEASE; GRIP STRENGTH; HORMONE RELEASE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; JOINT STIFFNESS; MORNING STIFFNESS; PATHOPHYSIOLOGY; PATIENT DECISION MAKING; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; BLOOD; DAILY LIFE ACTIVITY; DISABLED PERSON; PAIN; REVIEW; SECRETION;

ACTIVITIES OF DAILY LIVING; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CIRCADIAN RHYTHM; DISABLED PERSONS; HUMANS; HYDROCORTISONE; INFLAMMATION MEDIATORS; INTERLEUKIN-6; PAIN;

EID: 79955615918     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2011.566433     Document Type: Article

References (30)

1. Straub RH, Cutolo M. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum 2007;56:399-408.
2. Cutolo M, Otsa K, Aakre O, Sulli A. Nocturnal hormones and clinical rhythms in rheumatoid arthritis. Ann N Y Acad Sci 2005;1051:372-81. (Pubitemid 41362767)
3. Harkness JA, Richter MB, Panayi GS, Van de Pette K, Unger A, Pownall R, et al. Circadian variation in disease activity in rheumatoid arthritis. Br Med J (Clin Res Ed) 1982;284:551-4. (Pubitemid 12173542)
4. Straub RH, Cutolo M, Sulli A. Neuroendocrine immunology in rheumatic diseases. In: Bijlsma JWJ, editor. EULAR compendium on rheumatic diseases. London: BMJ Publishing Group Ltd, 2009:769-92.
5. Cutolo M, Villaggio B, Foppiani L, Briata M, Sulli A, Pizzorni C, et al. The hypothalamic-pituitary-adrenal and gonadal axes in rheumatoid arthritis. Ann N Y Acad Sci 2000;917:835-43.
6. Cutolo M, Foppiani L, Minuto F. Hypothalamic-pituitary-adrenal axis impairment in the pathogenesis of rheumatoid arthritis and polymyalgia rheumatica. J Endocrinol Invest 2002;25(10 Suppl):19-23.
7. Straub RH, Paimela L, Peltomaa R, Scholmerich J, Leirisalo-Repo M. Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheum 2002;46:654-62. (Pubitemid 34214248)
8. Neeck G, Federlin K, Graef V, Rusch D, Schmidt KL. Adrenal secretion of cortisol in patients with rheumatoid arthritis. J Rheumatol 1990;17:24-9. (Pubitemid 20070562)
9. Cutolo M, Straub RH, Bijlsma JW. Neuroendocrine-immune interactions in synovitis. Nature Clin Pract Rheumatol 2007;3:627-34.
10. Cutolo M, Straub RH. Insights into endocrine-immunological disturbances in autoimmunity and their impact on treatment. Arthritis Res Ther 2009;11:218.
11. Cutolo M, Seriolo B, Craviotto C, Pizzorni C, Sulli A. Circadian rhythms in RA. Ann Rheum Dis 2003;62:593-6. (Pubitemid 36760552)
12. Kirwan JR, Clarke L, Hunt LP, Perry MG, Straub RH, Jessop DS. Effect of novel therapeutic glucocorticoids on circadian rhythms of hormones and cytokines in rheumatoid arthritis. Ann N Y Acad Sci 2010;1193:127-33.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
14. Levin RW, Park J, Ostrov B, Reginato A, Baker DG, Bomalaski JS, et al. Clinical assessment of the 1987 American College of Rheumatology criteria for rheumatoid arthritis. Scand J Rheumatol 1996;25:277-81. (Pubitemid 26363301)
15. Yazici Y, Erkan D, Peterson MG, Kagen LJ. Morning stiffness: how common is it and does it correlate with physician and patient global assessment of disease activity? J Rheumatol 2001; 28:1468-9. (Pubitemid 32510527)
16. Berthelot JM, Bernelot-Moens HJ, Klarlund M, McGonagle D, Calin A, Schumacher HR, et al. Differences in understanding and application of 1987 ACR criteria for rheumatoid arthritis and 1991 ESSG criteria for spondylarthropathy. A pilot survey. Clin Exp Rheumatol 2002;20:145-50.
17. McInnes IB, Jacobs JWG, Woodburn J, van Laar JM. Treatment of rheumatoid arthritis. In: Bijlsma JWJ, editor. EULAR compendium on rheumatic diseases. London: BMJ Publishing Group Ltd, 2009:81-91.
18. Smolen JS, Landewe R, Breeveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease- modifying antirheumatic drugs. Ann Rheum Dis 2010; 69:964-75.
19. Saraux A, Berthelot JM, Chales G, Le Henaff C, Thorel JB, Hoang S, et al. Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum 2001;44:2485-91. (Pubitemid 33049326)
20. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria. Arthritis Rheum 2010;62:2569-81.
21. Khan NA, Yazici Y, Calvo-Alen J, Dadoniene J, Gossec L, Hansen TM, et al. Reevaluation of the role of duration of morning stiffness in the assessment of rheumatoid arthritis activity. J Rheumatol 2009;36:2435-42.
22. Yazici Y, Pincus T, Kautiainen H, Sokka T. Morning stiffness in patients with early rheumatoid arthritis is associated more strongly with functional disability than with joint swelling and erythrocyte sedimentation rate. J Rheumatol 2004;31: 1723-6. (Pubitemid 39202511)
23. Labitigan M, Sharaf PH, Swearingen C, Yazici Y. Rheumatoid arthritis patients who participated in randomized clinical trials in 1980s versus 2000s: clinical implications of similarities and differences. Ann Rheum Dis 2010;69(Suppl 3):508.
24. Boers M, Tugwell P, Felson DT, van Riel PL, Kirwan JR, Edmonds JP, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl 1994;41:86-9. (Pubitemid 24285550)
25. Felson DT, Anderson J, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40. (Pubitemid 23175613)
26. van der Heijde D, Ostergaard M. Assessment of disease activity and damage in inflammatory arthritis. In: Bijlsma JWJ, editor. EULAR compendium on rheumatic diseases. London: BMJ Publishing Group Ltd, 2009:182-201.
27. Rezaei H, van Vollenhoven RF, Forslind K, Albertsson K, Wallin H, Geborek P, et al. Radiological progression in patients with early RA and a good clinical response to MTX monotherapy: predictors and clinical implications. Ann Rheum Dis 2010; 69(Suppl 3):64.
28. Wallin H, van Vollenhoven RF, Albertsson K, Forslind K, Ernestam S, Petersson IF, et al. In early RA, patients with a good initial response to MTX monotherapy have excellent clinical outcomes over two years of therapy but radiological progression is not completely prevented. Ann Rheum Dis 2010;69(Suppl 3):212.
29. Rahman MU, Buchanan J, Doyle MK, Hsia E, Gathany T, Parasuraman S, et al. Historical trends of patient characteristics in anti-TNF clinical trials for rheumatoid arthritis: an analysis of the literature over the past 16 years. Ann Rheum Dis 2010;69(Suppl 3):530.
30. Westhoff G, Buttgereit F, Gromnica-Ihle E, Zink A. Morning stiffness and its influence on early retirement in patients with recent onset rheumatoid arthritis. Rheumatology 2008;47:980-4. (Pubitemid 351865919)